Larimar Therapeutics, Inc.
NASDAQLRMR heads into its Q1 2026 earnings today having shed more than a quarter of its value in a month — and short sellers have been adding to their positions throughout the slide. Bears have been busy. Short interest climbed 17% over the past week alone, reaching nearly 10% of the free float. That's a meaningful positioning shift into a clinical-stage biotech reporting results the…
LRMR cost to
Full pulse commentary is for ORTEX subscribers. The live data picture for LRMR below stays open — short interest, options flow, signals, and historical context.
Sign up free to read pulse →Short interest % of float, cost to borrow, utilization, and put/call ratio for LRMR are part of the ORTEX premium tier. Sign up to read the live numbers alongside the analysis.
Snapshot as of 20 May 2026
LRMR heads into its Q1 2026 earnings today having shed more than a quarter of its value in a month — and short sellers have been adding to their positions throughout the slide. Bears have been busy. Short interest…
Shorts are piling into LRMR at the fastest pace in months. Short interest has climbed 17.2% in a single week to 9.9% of free float. Wedbush trimmed its price target the same morning. Earnings land tomorrow. 8.5 million…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for LRMR — free to start on ORTEX.
Sign up for free →Open LRMR on ORTEX